ADAPTIVE BIOTECHNOLOGIES (ADPT)
US00650F1093 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 65.06M | 90.00M | 139.10M | 123.40M | 96.60M | |||
| Marketable Securities | 281.34M | 408.20M | 214.00M | 564.80M | 480.30M | |||
| Receivables | 37.97M | 40.10M | 17.40M | 10.00M | 12.70M | |||
| Inventories | 14.45M | 14.50M | 19.30M | 14.10M | 9.10M | |||
| Other Current Assets | 11.37M | 9.40M | 13.00M | 14.50M | 14.10M | |||
| Total Current Assets | 410.19M | 562.10M | 402.70M | 726.90M | 612.70M | |||
| Non-Current Assets | ||||||||
| PPE Net | 120.32M | 164.20M | 172.90M | 139.00M | 60.40M | |||
| Investments And Advances | N/A | 0.00 | 217.10M | 118.50M | 105.40M | |||
| Goodwill | 118.97M | 119.00M | 119.00M | 119.00M | 119.00M | |||
| Intangibles | 5.13M | 6.80M | 8.50M | 10.20M | 11.90M | |||
| Other Non-Current Assets | 6.52M | 4.50M | 3.00M | 2.70M | 2.90M | |||
| Total Non-Current Assets | 250.95M | 294.50M | 520.60M | 389.50M | 299.60M | |||
| TOTAL ASSETS | 661.13M | 856.60M | 923.30M | 1.12B | 912.30M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 31.61M | 37.40M | 29.60M | 26.90M | 10.40M | |||
| Accounts Payable | 7.72M | 8.10M | 3.30M | 3.20M | 4.50M | |||
| Other Current Liabilities | 48.69M | 64.30M | 80.90M | 75.10M | 63.40M | |||
| Total Current Liabilities | 88.02M | 109.80M | 113.80M | 105.20M | 78.30M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 36.60M | |||
| Other Non-Current Liabilities | 264.84M | 282.70M | 205.40M | 268.00M | 226.30M | |||
| Total Non-Current Liabilities | 264.72M | 282.70M | 205.60M | 267.90M | 263.00M | |||
| TOTAL LIABILITIES | 352.74M | 392.50M | 319.40M | 373.10M | 341.30M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.14B | -919.10M | -718.90M | -511.60M | -365.50M | |||
| Additional Paid In Capital | 1.45B | 1.39B | 1.32B | 1.25B | 935.80M | |||
| Minority Interest | -67.00K | 100.00K | 100.00K | N/A | N/A | |||
| Common Shares | 14.00K | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | 215.00K | -4.10M | -1.10M | 900.00K | 700.00K | |||
| Shares Outstanding | 145.08M | 143.10M | 141.40M | 137.60M | 125.20M | |||
| Tangible Book Value per Share | 1.27 | 2.36 | 3.37 | 4.46 | 3.52 | |||
| Total Shareholders' Equity | 308.40M | 464.20M | 604.00M | 743.30M | 571.00M | |||
| TOTAL LIABILITIES AND EQUITY | 661.13M | 856.60M | 923.30M | 1.12B | 912.30M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | 0.06 | |||
| Current Ratio | 4.66 | 5.12 | 3.54 | 6.91 | 7.83 | |||
| Return On Assets (ROA) | -34.07% | -23.37% | -22.45% | -13.10% | -7.63% | |||
| Return On Equity (ROE) | -73.04% | -43.13% | -34.32% | -19.67% | -12.19% | |||
All data in USD